The US Food and Drug Administration (FDA) has granted clearance for Asieris Pharmaceuticals’ Investigational New Drug (IND) application to begin a Phase Ib clinical trial of its oral drug, APL-1401, to treat moderately-to-severely active ulcerative colitis (UC).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,